Cerus Corp (CERS):企業の製品パイプライン分析

◆英語タイトル:Cerus Corp (CERS) - Product Pipeline Analysis, 2020 Update
◆商品コード:GDME26394PD
◆発行会社(調査会社):GlobalData
◆発行日:2021年1月
◆ページ数:40
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:Medical Devices
◆販売価格オプション(消費税別)
Site License(同一事業所内共有可)USD1,500 ⇒換算¥210,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD2,250 ⇒換算¥315,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Cerus Corp (Cerus) is a biomedical products company that focuses in the field of blood transfusion safety. It develops and commercializes Intercept Blood System, which reduces the risk of transfusion-transmitted infections by inactivating a wide range of pathogens including viruses, bacteria and parasites present in donated blood. The product is for use with three blood components,: platelets, plasma and red blood cells. Cerus’ Intercept blood system is marketed and sold by its direct sales force and distributors in several countries worldwide including the US, Belgium, Kuwait, France, Spain, Portugal, Switzerland, Commonwealth of Independent States (CIS) countries and other countries. Cerus is headquartered in Concord, California, the US.

This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:

- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company Cerus Corp
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.

Reasons to Buy:

- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Cerus Corp Company Overview
Cerus Corp Company Snapshot
Cerus Corp Pipeline Products and Ongoing Clinical Trials Overview
Cerus Corp – Pipeline Analysis Overview
Business Description
Cerus Corp – Key Facts
Cerus Corp – Major Products and Services
Cerus Corp Pipeline Products by Development Stage
Cerus Corp Ongoing Clinical Trials by Trial Status
Cerus Corp Pipeline Products Overview
INTERCEPT Blood System – Platelets
INTERCEPT Blood System – Platelets Product Overview
INTERCEPT Blood System – Platelets Clinical Trial
INTERCEPT Blood System – Red Blood Cells
INTERCEPT Blood System – Red Blood Cells Product Overview
INTERCEPT Blood System – Red Blood Cells Clinical Trial
INTERCEPT Blood System – Whole Blood
INTERCEPT Blood System – Whole Blood Product Overview
INTERCEPT Pathogen Reduced Cryoprecipitate – Poor Plasma
INTERCEPT Pathogen Reduced Cryoprecipitate – Poor Plasma Product Overview
Next Generation INTERCEPT Blood System
Next Generation INTERCEPT Blood System Product Overview
NTERCEPT Pathogen-Reduced Cryoprecipitated Fibrinogen Complex
NTERCEPT Pathogen-Reduced Cryoprecipitated Fibrinogen Complex Product Overview
Cerus Corp – Key Competitors
Cerus Corp – Key Employees
Cerus Corp – Key Employee Biographies
Cerus Corp – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Cerus Corp, Recent Developments
Apr 02, 2020: Cerus Corporation announces the inclusion of pathogen reduction technology in the ISBT working party recommendations for the preparation of COVID-19 convalescent plasma
Feb 18, 2020: U.S. Department of Defense awards funding for study to evaluate the use of INTERCEPT Plasma in traumatic burn resuscitation
Jan 23, 2020: Coronavirus inactivation reported in recent INTERCEPT Blood System publication in transfusion medicine
Jan 21, 2020: French Hemovigilance report highlights safety and effectiveness of INTERCEPT Platelets during first full year of 100% production and routine use
Oct 30, 2019: Cerus announces third quarter 2019 results
Oct 18, 2019: Cerus announces schedule of presentations at the 2019 AABB Annual Meeting
Sep 30, 2019: Cerus Corporation Applauds the Publication of the Final Guidance Document on Bacterial Safety Standards for Platelet Collection and Transfusion
Aug 01, 2019: Cerus announces record second quarter 2019 results
Jun 24, 2019: Cerus announces presentations highlighting INTERCEPT Blood System at the 29th Regional Congress of the ISBT
Jun 03, 2019: Cerus announces new corporate brand and global headquarters
Appendix
Methodology
About GlobalData
Contact Us
Disclaimer

List of Tables
Cerus Corp Pipeline Products and Ongoing Clinical Trials Overview
Cerus Corp Pipeline Products by Equipment Type
Cerus Corp Pipeline Products by Indication
Cerus Corp Ongoing Clinical Trials by Trial Status
Cerus Corp, Key Facts
Cerus Corp, Major Products and Services
Cerus Corp Number of Pipeline Products by Development Stage
Cerus Corp Pipeline Products Summary by Development Stage
Cerus Corp Ongoing Clinical Trials by Trial Status
Cerus Corp Ongoing Clinical Trials Summary
INTERCEPT Blood System - Platelets - Product Status
INTERCEPT Blood System - Platelets - Product Description
INTERCEPT Blood System - Platelets - A Randomized, Multi-center, Multi-Stage, Controlled, In Vivo Study to Assess the Recovery and Survival of Radiolabeled Autologous INTERCEPT Apheresis Platelet Components Suspended in 100% Plasma Stored for up to 7 Days
INTERCEPT Blood System - Red Blood Cells - Product Status
INTERCEPT Blood System - Red Blood Cells - Product Description
INTERCEPT Blood System - Red Blood Cells - A Randomized, Double-blinded, Controlled, Parallel Group, Non-inferiority, Phase III Study to Evaluate the Efficacy and Safety of the INTERCEPT Blood System for Red Blood Cells in Patients Undergoing Complex Cardiac Surgery Procedures
INTERCEPT Blood System - Red Blood Cells - Measurement of the Recovery and Lifespan of Red Blood Cells from Pathogen-reduced, Stored Blood Units Using Cellular Biotinylation
INTERCEPT Blood System - Red Blood Cells - Randomized, Double-blind, Controlled, Parallel Group Study with the INTERCEPT Blood System for RBCs in Regions at Potential Risk for Zika Virus Transfusion-transmitted Infections and Treatment Use Open-label Extension Study
INTERCEPT Blood System - Whole Blood - Product Status
INTERCEPT Blood System - Whole Blood - Product Description
INTERCEPT Pathogen Reduced Cryoprecipitate - Poor Plasma - Product Status
INTERCEPT Pathogen Reduced Cryoprecipitate - Poor Plasma - Product Description
Next Generation INTERCEPT Blood System - Product Status
Next Generation INTERCEPT Blood System - Product Description
NTERCEPT Pathogen-Reduced Cryoprecipitated Fibrinogen Complex - Product Status
NTERCEPT Pathogen-Reduced Cryoprecipitated Fibrinogen Complex - Product Description
Cerus Corp, Key Employees
Cerus Corp, Key Employee Biographies
Cerus Corp, Subsidiaries
Glossary

★海外企業調査レポート[Cerus Corp (CERS):企業の製品パイプライン分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Haier Electronics Group Co Ltd:企業の戦略・SWOT・財務情報
    Haier Electronics Group Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Haier Electronics Group Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Global Foundries Inc:企業のM&A・事業提携・投資動向
    Global Foundries Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Global Foundries Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A …
  • Eurobio Scientific SA (ALEHT):企業の財務・戦略的SWOT分析
    Summary Eurobio Scientific SA (Eurobio), formerly Diaxonhit SA, a subsidiary of Hellenic Petroleum SA, is a biotechnology company that provides diagnostic products. The company provides products such as TQS, used in treatment of teanus and BJI InoPlex, used for the treatment of prosthetic infection. …
  • Solon Eiendom ASA (SOLON):企業の財務・戦略的SWOT分析
    Solon Eiendom ASA (SOLON) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Press Ganey Associates, Inc.:企業の戦略的SWOT分析
    Press Ganey Associates, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produc …
  • ET Solar Group Corporation:電力:M&Aディール及び事業提携情報
    Summary ET Solar Group Corporation (ET Solar) is a provider of renewable energy equipment and services. The company produces a variety of photovoltaic (PV) modules based on global standards such as IEC, TUV, VDE, and UL. It also provides horizontally integrated project development; finance and inves …
  • Ittehad Chemicals Ltd (ICL):企業の財務・戦略的SWOT分析
    Ittehad Chemicals Ltd (ICL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • LipimetiX Development Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary LipimetiX Development Inc (LipimetiX), formerly LipimetiX LLC is a biopharmaceutical company that develops drugs to treat refractory hypercholesterolemia and hypertriglyceridemia, acute pancreatitis, coronary artery, and peripheral artery diseases. The company develops drugs based on chimeri …
  • Power Grid Corporation of India Limited:企業の戦略・SWOT・財務情報
    Power Grid Corporation of India Limited - Strategy, SWOT and Corporate Finance Report Summary Power Grid Corporation of India Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT a …
  • Bend Research Inc-製薬・医療分野:企業M&A・提携分析
    Summary Bend Research Inc (Bend Research), a subsidiary of Capsugel Inc is a provider of drug delivery technologies and formulation development services. The company offers services such as formulation science, dosage form development, process development, engineering, cGMP manufacturing, bioprocess …
  • Abionic SA-医療機器分野:企業M&A・提携分析
    Summary Abionic SA (Abionic) is a medical device company that develops, produces, and markets in vitro diagnostic devices. The company offers products such as abioSCOPE, IVD capsule, abioGUIDE, abioGUIDE application for android, iPhone & iPad, and accessories. Its abioSCOPE in vitro tests are design …
  • Lanco Infratech Ltd:発電所・企業SWOT分析
    Lanco Infratech Ltd – Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees …
  • Sasol Ltd (SOL)-エネルギー分野:企業M&A・提携分析
    Summary Sasol Ltd (Sasol) is an integrated energy and chemical company. It develops and commercializes technologies; and builds and operates facilities to produce a range of products, including liquid fuels, chemicals, and low-carbon electricity. The company’s product offerings include olefins and s …
  • Halliburton Co (HAL)-石油・ガス分野:企業M&A・提携分析
    Summary Halliburton Company (Halliburton) is an oilfield services company. The company serves the upstream oil and gas industry throughout the lifecycle of the reservoir, from identifying hydrocarbons and managing geological data, to drilling and formation evaluation, well construction and completio …
  • Younicos AG:電力:M&Aディール及び事業提携情報
    Summary Younicos AG (Younicos), a subsidiary of Aggreko Plc, is a provider of smart energy and grid solutions based on battery storage technology. The company offers Y-Cube plug and play energy storage solution, Y-Station building solution, and Y-Q software platform. It also provides battery packs u …
  • Fujifilm Holdings Corporation (FUJIY):製薬・医療:M&Aディール及び事業提携情報
    Summary Fujifilm Holdings Corp (Fujifilm) sales and manufactures imaging systems and document solution equipment. The company’s major products are color films, color paper and chemicals, photofinishing equipment, electronic imaging and optical devices, TV camera lenses, security lenses, healthcare p …
  • Saudi Kayan Petrochemical Co (2350):企業の財務・戦略的SWOT分析
    Summary Saudi Kayan Petrochemical Co (Saudi Kayan) is a petrochemical company that manufactures and markets specialty chemicals. The company offers products such as ethanolamines, ethoxylates, phenol, cumene, polycarbonate, ethylene, propylene, polyethylene, monoethanolamine, diethanolamine, trietha …
  • Vinacomin – Coc Sau Coal:企業の戦略・SWOT・財務分析
    Vinacomin - Coc Sau Coal - Strategy, SWOT and Corporate Finance Report Summary Vinacomin - Coc Sau Coal - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Global Payments Inc (GPN):企業の財務・戦略的SWOT分析
    Global Payments Inc (GPN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • OBJ Ltd (OBJ):企業の財務・戦略的SWOT分析
    Summary OBJ Ltd (OBJ) is a developer of magnetic micro-array drug and ingredient delivery technologies. The company offers services such as drug or ingredient profiling in skin, laboratory facilities and capabilities, formulation development, product development, product optimisation, and pre-commer …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆